Accessibility StatementSkip Navigation Ginkgo and Partners to Develop Monoclonal Antibody Biomanufacturing Innovations and to Produce an Anti- Filovirus Medical Countermeasure BOSTON, Nov. 3, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) announced today that it has been awarded a contract through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to develop innovations that strengthen and reduce the costs of dom ...